Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03024996) enrolled 778 people who had been treated for kidney cancer (renal cell carcinoma) and were at risk of it returning. Participants were randomly assigned to receive either atezolizumab (390 people) or a placebo — an inactive lookalike treatment (388 people). The trial's main goal was to measure "disease-free survival," which means how long participants went without their cancer coming back or dying from any cause. The reported data shows that, for the primary outcome of investigator-assessed disease-free survival, the atezolizumab group had a reported median of 57.2 months, compared with 49.5 months in the placebo group. (A "median" here means the midpoint — half of participants in each group reached that time point without an event, and half did not.) In a subgroup of participants whose tumour tissue showed a certain protein marker (called PD-L1 IC1/2/3, meaning at least 1% of immune cells in the tumour expressed this protein), the reported figures were 57.2 months for the atezolizumab group and 47.9 months for the placebo group. For several other secondary outcomes — including overall survival (how long participants lived overall), an independent review of disease-free survival, and a related measure called event-free survival — the data was not reported as a numeric figure in the submitted results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 36099926) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Kidney Cancer Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are generally healthy and able to carry out daily activities with little or no limitation (confirm with trial site regarding the specific fitness score required)
- Your kidney cancer has been confirmed by a lab test and is either a "clear cell" or "sarcomatoid" type, has not been treated before with any pre- or post-surgery therapy, and is considered high risk for coming back
- You have had surgery to remove all or part of your kidney, possibly including nearby lymph nodes
- Scans of your pelvis, abdomen, and chest taken within the last 4 weeks show no remaining cancer or spread to other parts of the body
- If you had surgery to remove a cancer that had spread, a brain scan taken within the last 4 weeks shows no cancer in the brain
- You have fully recovered from your kidney or other cancer surgery within 12 weeks before joining the trial
Who may not be able to join:
- You have kidney tumors in both kidneys at the same time linked to an inherited condition, such as von Hippel-Lindau disease
- You have received any approved cancer treatment, including chemotherapy or hormone therapy, within the last 3 weeks
- You have taken part in another clinical trial or received an experimental treatment within the last 28 days (or longer, depending on the treatment)
- You have had a different type of cancer in the last 5 years (other than kidney cancer)
- You have a history of an autoimmune disease (a condition where your immune system attacks your own body)
- You have previously had a stem cell transplant or received a donated organ
- You have a history of certain lung conditions, such as pulmonary fibrosis, drug-related lung inflammation, or a specific type of lung scarring, or your recent chest scan shows signs of active lung inflammation
- You have tested positive for HIV
- You currently have active hepatitis B or hepatitis C
- You currently have active tuberculosis (TB)
- You had a serious infection requiring hospitalisation within the last 4 weeks
- You have had a major surgical procedure within the last 4 weeks, or are expected to need one during the trial (other than for diagnosis)
- You have received a live vaccine within the last 4 weeks
- You have another significant health condition that could make the experimental treatment unsafe or affect the trial results (confirm with trial site)
- You have previously been treated with certain types of immunotherapy drugs that target specific immune pathways (such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 treatments) (confirm with trial site for full list)
- You have taken immune-boosting medications, such as interferons or interleukin-2, within the last 6 weeks
- You have taken immune-suppressing medications — such as steroids, methotrexate, or similar drugs — within the last 2 weeks, or expect to need them during the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Investigator-assessed Disease-Free Survival (DFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.